PHARMAMED: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
PHARMAMED
Largest movements
- Cash +€152,393
up €152,393 (+58.9%), from €258,589 to €410,981
mainly Net result for the year (+€186,710) and Depreciation (+€62,317)
- Receivables within one year -€33,740
down €33,740 (-6.6%), from €514,902 to €481,162
of which Other amounts receivable: -€21,191
- Tangible fixed assets -€27,652
down €27,652 (-20.1%), from €137,592 to €109,940
of which Furniture and vehicles: -€26,494
- Stocks and contracts +€21,253
up €21,253 (+5.6%), from €380,000 to €401,253
- Other debts +€49,876
up €49,876 (+43.3%), from €115,059 to €164,936
- Trade debts +€47,032
up €47,032 (+6.8%), from €688,682 to €735,714
- Profit (loss) carried forward +€36,710
up €36,710 (+133.8%), from €27,432 to €64,141
- Debts after one year -€16,201
down €16,201 (-55.7%), from €29,070 to €12,869
- Gross operating margin +€123,225
up €123,225 (+30.1%), from €408,778 to €532,003
- Staff costs +€54,963
up €54,963 (+26.9%), from €203,985 to €258,949
- Other operating charges -€23,361
down €23,361 (-74.7%), from €31,275 to €7,914
- Financial income -€21,353
down €21,353 (-71.4%), from €29,902 to €8,549
- Depreciation +€11,697
up €11,697 (+23.1%), from €50,620 to €62,317
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,326,154 | €1,446,671 | +€120,517 | +9.1% |
| Fixed assets | 21/28 | €172,663 | €145,539 | -€27,124 | -15.7% |
| Intangible fixed assets | 21 | €29,711 | €30,239 | +€529 | +1.8% |
| Tangible fixed assets | 22/27 | €137,592 | €109,940 | -€27,652 | -20.1% |
| Plant, machinery and equipment | 23 | €1,961 | €1,252 | -€709 | -36.1% |
| Furniture and vehicles | 24 | €131,619 | €105,125 | -€26,494 | -20.1% |
| Other tangible fixed assets | 26 | €4,012 | €3,563 | -€450 | -11.2% |
| Financial fixed assets | 28 | €5,360 | €5,360 | = | 0.0% |
| Current assets | 29/58 | €1,153,491 | €1,301,131 | +€147,641 | +12.8% |
| Stocks and contracts in progress | 3 | €380,000 | €401,253 | +€21,253 | +5.6% |
| Stocks | 30/36 | €380,000 | €401,253 | +€21,253 | +5.6% |
| Amounts receivable within one year | 40/41 | €514,902 | €481,162 | -€33,740 | -6.6% |
| Trade receivables | 40 | €475,521 | €462,972 | -€12,549 | -2.6% |
| Other amounts receivable | 41 | €39,382 | €18,191 | -€21,191 | -53.8% |
| Cash at bank and in hand | 54/58 | €258,589 | €410,981 | +€152,393 | +58.9% |
| Deferred charges and accrued income | 490/1 | - | €7,735 | +€7,735 | |
| Total equity and liabilities | 10/49 | €1,326,154 | €1,446,671 | +€120,517 | +9.1% |
| Equity | 10/15 | €402,716 | €439,425 | +€36,710 | +9.1% |
| Contributions | 10/11 | €62,000 | €62,000 | = | 0.0% |
| Capital | 10 | €62,000 | €62,000 | = | 0.0% |
| Issued capital | 100 | €62,000 | €62,000 | = | 0.0% |
| Reserves | 13 | €313,284 | €313,284 | = | 0.0% |
| Non-distributable reserves | 130/1 | €6,200 | €6,200 | = | 0.0% |
| Legal reserve | 130 | €6,200 | €6,200 | = | 0.0% |
| Tax-exempt reserves | 132 | €6,593 | €6,593 | = | 0.0% |
| Distributable reserves | 133 | €300,491 | €300,491 | = | 0.0% |
| Profit (loss) carried forward | 14 | €27,432 | €64,141 | +€36,710 | +133.8% |
| Amounts payable | 17/49 | €923,438 | €1,007,245 | +€83,807 | +9.1% |
| Amounts payable after more than one year | 17 | €29,070 | €12,869 | -€16,201 | -55.7% |
| Financial debts | 170/4 | €29,070 | €12,869 | -€16,201 | -55.7% |
| Amounts payable within one year | 42/48 | €894,369 | €994,377 | +€100,008 | +11.2% |
| Current portion of amounts payable after more than one year | 42 | €21,015 | €16,201 | -€4,814 | -22.9% |
| Trade debts | 44 | €688,682 | €735,714 | +€47,032 | +6.8% |
| Suppliers | 440/4 | €688,682 | €735,714 | +€47,032 | +6.8% |
| Taxes, remuneration and social security | 45 | €69,612 | €77,526 | +€7,914 | +11.4% |
| Taxes | 450/3 | €41,990 | €54,364 | +€12,374 | +29.5% |
| Remuneration and social security | 454/9 | €27,622 | €23,163 | -€4,460 | -16.1% |
| Other amounts payable | 47/48 | €115,059 | €164,936 | +€49,876 | +43.3% |
| Non-recurring operating income | 76A | €239 | - | -€239 | |
| Remuneration, social security and pensions | 62 | €203,985 | €258,949 | +€54,963 | +26.9% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €50,620 | €62,317 | +€11,697 | +23.1% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | €7,864 | €1,234 | -€6,630 | -84.3% |
| Other operating charges | 640/8 | €31,275 | €7,914 | -€23,361 | -74.7% |
| Non-recurring operating charges | 66A | €80 | - | -€80 | |
| Gross operating margin | 9900 | €408,778 | €532,003 | +€123,225 | +30.1% |
| Operating profit (loss) | 9901 | €114,954 | €201,589 | +€86,635 | +75.4% |
| Financial income | 75/76B | €29,902 | €8,549 | -€21,353 | -71.4% |
| Recurring financial income | 75 | €29,902 | €8,549 | -€21,353 | -71.4% |
| Financial charges | 65/66B | €9,611 | €5,674 | -€3,937 | -41.0% |
| Recurring financial charges | 65 | €9,611 | €5,674 | -€3,937 | -41.0% |
| Profit (loss) for the period before taxes | 9903 | €135,245 | €204,464 | +€69,219 | +51.2% |
| Income taxes | 67/77 | €7,813 | €17,754 | +€9,941 | +127.2% |
| Profit (loss) for the period | 9904 | €127,432 | €186,710 | +€59,278 | +46.5% |
| Profit (loss) for the period to be appropriated | 9905 | €127,432 | €186,710 | +€59,278 | +46.5% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 28 September 2026 via checked.be.